IRIS
BREMBILLA, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.303
AS - Asia 1.491
NA - Nord America 1.310
SA - Sud America 204
AF - Africa 33
OC - Oceania 10
Totale 5.351
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 1.261
US - Stati Uniti d'America 1.245
IT - Italia 569
SG - Singapore 521
CN - Cina 451
BR - Brasile 161
HK - Hong Kong 151
VN - Vietnam 109
BD - Bangladesh 108
FR - Francia 72
SE - Svezia 72
GB - Regno Unito 68
DE - Germania 66
NL - Olanda 55
FI - Finlandia 45
IN - India 38
CA - Canada 37
ES - Italia 20
JP - Giappone 18
TR - Turchia 17
PL - Polonia 16
IQ - Iraq 14
AR - Argentina 13
MX - Messico 13
AT - Austria 11
IE - Irlanda 11
ZA - Sudafrica 10
EC - Ecuador 9
AE - Emirati Arabi Uniti 8
LT - Lituania 8
BE - Belgio 7
CO - Colombia 7
EG - Egitto 7
ID - Indonesia 7
AU - Australia 6
MY - Malesia 6
PK - Pakistan 6
IL - Israele 5
PY - Paraguay 5
UZ - Uzbekistan 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
NZ - Nuova Zelanda 4
PH - Filippine 4
UA - Ucraina 4
VE - Venezuela 4
AZ - Azerbaigian 3
BG - Bulgaria 3
CH - Svizzera 3
CR - Costa Rica 3
KE - Kenya 3
KR - Corea 3
MD - Moldavia 3
SA - Arabia Saudita 3
TN - Tunisia 3
TW - Taiwan 3
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
LV - Lettonia 2
MA - Marocco 2
NP - Nepal 2
PR - Porto Rico 2
AL - Albania 1
AO - Angola 1
BY - Bielorussia 1
BZ - Belize 1
CL - Cile 1
CY - Cipro 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
NI - Nicaragua 1
PE - Perù 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 5.351
Salva come PNG Salva come JPEG
Città #
Singapore 319
Moscow 233
Ashburn 196
Dallas 174
Hong Kong 149
San Jose 146
Milan 128
New York 93
Beijing 72
Shanghai 66
Los Angeles 54
Rome 49
Lauterbourg 41
Hefei 40
Ho Chi Minh City 38
Council Bluffs 29
Hanoi 27
Naples 27
Santa Clara 27
Orem 25
São Paulo 23
Boardman 22
Turku 21
Munich 20
Bari 17
Brooklyn 17
Buffalo 16
Lawrence 16
Princeton 16
Turin 16
Chennai 15
Denver 14
Frankfurt am Main 14
Montreal 14
Helsinki 13
Warsaw 13
Bologna 12
Brescia 12
Tokyo 12
Toronto 12
Dublin 11
Manchester 11
Poplar 11
Suzhou 11
Valencia 10
Washington 10
Amsterdam 9
Atlanta 9
Nuremberg 9
Ankara 8
Mexico City 8
Phoenix 8
Stockholm 8
Belo Horizonte 7
Chicago 7
Guangzhou 7
Lappeenranta 7
Padova 7
Palermo 7
Seattle 7
The Dalles 7
Tianjin 7
Baghdad 6
Barnet 6
Columbus 6
Damietta 6
Falkenstein 6
London 6
Brussels 5
Changsha 5
Charleston 5
Da Nang 5
Dhaka 5
Mumbai 5
Rio de Janeiro 5
Tashkent 5
Trieste 5
Abu Dhabi 4
Asunción 4
Auckland 4
Bexley 4
Bolzano 4
Catania 4
Cesano Boscone 4
Erbil 4
Fortaleza 4
Genoa 4
Haiphong 4
Houston 4
Jiaxing 4
Johannesburg 4
Kuala Lumpur 4
New Delhi 4
Paris 4
Quito 4
Secaucus 4
Sydney 4
Bergamo 3
Birmingham 3
Boston 3
Totale 2.604
Salva come PNG Salva come JPEG
Nome #
Simplification of prostate MRI protocol and development of a novel MRI technique for prostate cancer detection and characterization 398
Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy 216
[68Ga]Ga-PSMA and [68Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration 184
Role of [68Ga]Ga-PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer 160
68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data 160
A NOVEL MODEL INTEGRATING CLINICAL, MP-MRI, AND EPIGENOMIC FEATURES TO PREDICT LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION 158
How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series 142
External validation of a convolutional neural network for the automatic segmentation of intraprostatic tumor lesions on 68Ga-PSMA PET images 131
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer 129
Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era? 127
Preliminary results of an ongoing prospective clinical trial on the use of68ga-psma and68ga-dota-rm2 pet/mri in staging of high-risk prostate cancer patients 124
Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study 121
Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series 120
Diagnostic accuracy of fully hybrid [68Ga]Ga-PSMA-11 PET/MRI and [68Ga]Ga-RM2 PET/MRI in patients with biochemically recurrent prostate cancer: a prospective single-center phase II clinical trial 119
Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study 119
Quantification of Prostate Cancer Metabolism Using 3D Multiecho bSSFP and Hyperpolarized [1-13 C] Pyruvate: Metabolism Differs Between Tumors of the Same Gleason Grade 114
Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion? 114
Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer 112
Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study 112
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis 106
Pancreatic metastases after surgery for renal cell carcinoma: survival and pathways of progression 104
Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database 98
The Challenge of External Generalisability: Insights from the Bicentric Validation of a [68Ga]Ga-PSMA-11 PET Based Radiomics Signature for Primary Prostate Cancer Characterisation Using Histopathology as Reference 95
A machine learning-based analysis for the definition of an optimal renal biopsy for kidney cancer 95
Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer 94
Interreader variability in prostate MRI reporting using Prostate Imaging Reporting and Data System version 2.1 92
There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies 91
Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer 90
Advanced Imaging Analysis in Prostate MRI: Building a Radiomic Signature to Predict Tumor Aggressiveness 87
Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization 86
Beyond diagnosis: is there a role for radiomics in prostate cancer management? 82
Head-to-head comparison of nephrometry scores for partial nephrectomy: implications for clinical guidelines 76
The added value of artificial intelligence using Quantib Prostate for the detection of prostate cancer at multiparametric magnetic resonance imaging 69
Embolization of superior rectal arteries for transfusion dependent haemorrhoidal bleeding in severely cardiopathic patients: a new field of application of the “emborrhoid” technique 69
Tailored use of PSA density according to multiparametric MRI index lesion location: results of a large, multi-institutional series 66
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI 66
AI-Assisted vs Unassisted Identification of Prostate Cancer in Magnetic Resonance Images 65
Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging-Reporting and Data System and biopsy history 63
Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer 63
[18F]FDG PET/MRI in Endometrial Cancer: Prospective Evaluation of Preoperative Staging, Molecular Characterization and Prognostic Assessment 58
US/TOF-PET endorectal probe compatible with MR, for diagnosis and staging of the prostate cancer 57
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial 54
Diagnostic Accuracy of Fully Hybrid PET/MRI with [68 Ga]Ga-PSMA-11 and [68 Ga]Ga-RM2 in Detecting Primary Prostate Cancer: A Phase 2 Trial with Histology as Gold Standard 54
Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection 51
ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI 49
MpMRI of the prostate: is there a role for semi-quantitative analysis of DCE-MRI and late gadolinium enhancement in the characterisation of prostate cancer? 49
Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging 45
Tackling Interobserver Variability in Multiparametric Magnetic Resonance Imaging (MRI): Is MRI Even Better than We Think for Prostate Cancer Diagnosis? 45
Less Is More: Enhancing Prostate MRI Without Intravenous Contrast 43
Global Variation in Magnetic Resonance Imaging Quality of the Prostate 42
Therapeutic EUS: Biliary drainage - The interventional radiologist's perspective 42
AI-powered prostate cancer detection: a multi-centre, multi-scanner validation study 40
Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a prospective feasibility study (ReIMAGINE study) 37
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer 36
ESR Essentials: using the right scoring system in prostate MRI—practice recommendations by ESUR 31
Is MRI ready to replace biopsy during active surveillance? 30
Dissemination of endometrial cancer MRI staging guidelines among young radiologists: an ESUR Junior Network survey 30
Improving image quality in prostate MRI: the time is now 30
Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study 29
Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study 28
Extraprostatic incidental findings on prostate mpMRI: A pictorial review from the ESUR junior network 25
null 23
Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: A prospective cohort study 20
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC) 18
The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses 15
Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score 11
PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI 9
First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer 7
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer 5
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study 3
Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer 2
Totale 5.535
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.659
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.659
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202212 0 4 1 2 0 1 3 1 0 0 0 0
2022/2023183 40 22 13 10 3 13 10 13 4 5 32 18
2023/2024363 6 22 36 33 28 76 10 30 5 40 31 46
2024/2025911 68 29 35 43 72 89 140 99 117 48 86 85
2025/20264.045 209 177 194 318 387 184 341 378 1.162 304 216 175
Totale 5.535